linjc16/ctgov huggingface dataset:
Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections

Study Overview
=================
Brief Summary
-----------------
The goal of this longitudinal study is to assess headache and facial pain features in patients with upper respiratory tract infections (URTI). The main question it aims to answer are: What is the phenotype of headache / facial pain in URTIs Does the above mentioned phenotype is associated with: aetiologic factor (virus), type of URTI headache/facial pain experienced by patients in the past. Participants will: answer standardized questions, undergo physical examination, have a swab test performend for antigens of common viruses causing URTI.

Official Title
-----------------
Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections - a Cross-sectional Study in Primary Care Setting

Conditions
-----------------
Upper Respiratory Tract Infections

Intervention / Treatment
-----------------
* Diagnostic Test: Swab test for viral antigens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: URTI confirmed by primary care physician Informed consent to participate in the study Exclusion Criteria: chronic or recurrent upper respiratory tract disorders neoplasms signs or symptoms of a serious neurologic or psychiatric disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>Patients reporting for primary care assessment because of URTI. | Diagnostic Test: Swab test for viral antigens<br>* No intervention except for a routine examination and viral testing is planned.<br>* Other names: Physical examination;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with one of the specified pain phenotypes | Percentage of patients with one of the specified pain phenotypes (migraine-like/tension-type-like/trigeminal cephalalgia-like) | A single assessment during primary care physician office 1 day visit. |
Wrist Splint and Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop

Study Overview
=================
Brief Summary
-----------------
To determine effectiveness of wrist splint and occupational therapy to improve pain, mobility and functional status in patients with wrist drop.

Official Title
-----------------
Effectiveness of Wrist Splint and Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop

Conditions
-----------------
Wrist-Drop

Intervention / Treatment
-----------------
* Diagnostic Test: Wrist Splint
* Diagnostic Test: Occupational Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • People with wrist drop People between 20 to 40 years will be included (male and female) Post-operative patients (nerve grafting and plastic surgery) Patients with findings of nerve compression will be included Exclusion Criteria: • People with nerve injuries other than radial nerve such as ulnar or median nerve People suffering with other neurological disorders. People who are not able to follow instructions Any traumatic history Diabetic patients, thyroid issues, pregnant females

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Wrist Splint<br> | Diagnostic Test: Wrist Splint<br>* Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop<br>|
| Experimental: Occupational Therapy<br> | Diagnostic Test: Occupational Therapy<br>* Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DASH scale (0-100) | DASH questionnaire for function on the scale of (0-100) worst zero- hundred normal | 6 Months | 
| VAS on the scale (1-10) | VAS for pain for pain (0-10) 0 for normal, 10 for worst pain | 6 Months |
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Study Overview
=================
Brief Summary
-----------------
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.

Detailed Description
-----------------
At the time of enrollment in the Registry, participant records will be queried for retrospective information about the participant's medical history and AQP4+ NMOSD treatment history for the time period beginning 1 year prior to ALXN-C5IT initiation through Registry enrollment. The duration of data collection for the Registry will be approximately 5 years from the day the last participant is enrolled.

Official Title
-----------------
A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

Conditions
-----------------
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is ≥ 18 years of age at the time of enrollment in the Registry. Participant must have a confirmed diagnosis of AQP4+ NMOSD. At the time of enrollment in the Registry, participants must be receiving treatment with ALXN-C5IT for the purpose of chronic relapse prevention in a manner consistent with the local label. Specifically, they should have received at least 1 dose of eculizumab within 4 weeks prior to enrollment or at least 1 dose of ravulizumab within 12 weeks prior to enrollment. Participants must have both the following historical data available to be enrolled in the Registry: ALXN-C5IT dosing information since initiation and number and types of relapses from 1 year prior to ALXN-C5IT initiation through Registry enrollment. Exclusion Criteria: Participants currently enrolled in an interventional clinical study for the treatment of AQP4+ NMOSD in which the intervention is a drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Annualized Relapse Rate (ARR) | The ARR is defined as the total number of relapses divided by the total number of participant-years. | Up to approximately 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NMOSD, Neuromyelitis Optica Spectrum Disorder, C5 Inhibitor Therapies, AQP4+ NMOSD, Patient Registry, Alexion C5IT, Soliris
FDG-PET in the Diagnosis of Autoimmune Encephalitis

Study Overview
=================
Brief Summary
-----------------
The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is: •is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.

Official Title
-----------------
FDG-PET in the Diagnosis of Autoimmune Encephalitis

Conditions
-----------------
Autoimmune Encephalitis

Intervention / Treatment
-----------------
* Diagnostic Test: FDG-PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of autoimmune encephalitis according to clinical criteria Brain magnetic resonance imaging performed between clinical presentation and treatment Cerebrospinal fluid analysis performed between clinical presentation and treatment Brain FDG-PET performed between clinical presentation and treatment Autoantibodies testing performed between clinical presentation and treatment Exclusion Criteria: Refusal to give consent for the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Autoimmune Encephalitis patients<br>Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory. | Diagnostic Test: FDG-PET<br>* Brain FDG-PET<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SPM analysis of brain metabolic pattern | Pattern of brain metabolism in patients with autoimmune encephalitis compared with healthy controls and patients with Alzheimer's disease, drawn from validated published databases | up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity of basal ganglia hypermetabolism | Sensitivity of basal ganglia hypermetabolism for the diagnosis of autoimmune encephalitis | up to 6 months | 
| Diagnostic delay | Comparison of diagnostic delay with and without FDG-PET | up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SPM, Autoimmune Encephalitis, FDG-PET
Study of Speech Function in Epileptic Patients Based on Stereoelectroencephalography Signal

Study Overview
=================
Brief Summary
-----------------
Based on stereoelectroencephalography model in the treatment of epilepsy patients, this study conducted language-related experimental studies without interfering with normal monitoring treatment. Meanwhile, voice data and intracranial electrophysiological data were collected for analysis. To study the mechanism related to the language function of patients, try to establish a model to decode the intracranial electrophysiological data related to language.

Official Title
-----------------
Study of Speech Function in Epileptic Patients Based on Stereoelectroencephalography Signal

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Behavioral: Speech
* Device: Stereoelectroencephalography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with focal refractory epilepsy also need preoperative evaluation with SEEG Exclusion Criteria: History of major depression or psychiatric disorders and medication that causes symptoms of psychiatric disorders Patients with severe cognitive impairment (MMSE score ≤15), unable to complete the language function test

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epileptic<br>Epileptic with stereoelectroencephalography | Behavioral: Speech<br>* Patients read specific words and sentences<br>Device: Stereoelectroencephalography<br>* Using stereoelectroencephalography to record the Intracranial EEG of the patient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phonetic Feature Encoding in Human Superior Temporal Gyrus | Phonetic Feature Encoding in Human Superior Temporal Gyrus | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epilepsy, Stereoelectroencephalography, Speech
Association of Gestational Cardiovascular Health With Pregnancy Outcomes

Study Overview
=================
Brief Summary
-----------------
Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations. Recently, the American Heart Association proposed the latest cardiovascular health assessment indicator Life's Essential 8. However, there is still a lack of application data for pregnant women. This project intends to explore the application potential of Life's Essential 8 in cardiovascular health assessment of pregnant women and establish appropriate gestaional cardiovascular health standards.

Official Title
-----------------
Association of Cardiovascular Health During Pregnancy With Perinatal Outcomes---a Birth Cohort Study

Conditions
-----------------
Pregnant Women

Intervention / Treatment
-----------------
* Other: Questionnaire survey and specimen collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Maternal age: 20-49 years; Natural conception; Single pregnancy; Plan to have routine prenatal examinations and give birth in the research center; Exclusion Criteria: Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy; Assisted reproduction; Multiple pregnancy; Fetus has a known deformity or genetic defects; Incomplete clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal outcomes | Including pregnancy-induced hypertension, preterm delivery, abortion, delivery way and so on. They are diagnosed by clinicians and the data is gathered from medical records. | Through delivery completion, up to 42 weeks | 
| Neonatal outcomes | Birth weight（in gram), birth height (in centimetre), gestational week (in week) and other neonatal diseases. They are diagnosed by clinicians and the data is gathered from medical records. | Through delivery completion, up to 42 weeks |
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.

Detailed Description
-----------------
This is a non-randomized, prospective, multicenter complementary-study of the REBALANCE Registry. Patients who have been implanted with a CRT device at least 6-months prior to enrollment are eligible for this complementary-study. Up to 150 subjects will be enrolled. Data should be obtained from evaluations taken prior to implant, at implant, and every six months after device implant, up to the 36-month visit at which time each patient will be exited from the study.

Official Title
-----------------
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence. A Post-Market Registry With the Barostim™ System

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: Barostim™ System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients can be included if they were implanted with a cardiac resynchronization therapy (CRT) device at least six months (180 days) prior to informed consent and are planned for a de novo Barostim System implantation. Patients must sign an informed consent form before implantation with the Barostim System in order to participate in this study. Exclusion Criteria: Patients cannot be enrolled and active in another (e.g. device, pharmaceutical, or biological) clinical study unless approved by the CVRx Clinical department.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Device: Barostim™ System<br>Implantation of the Barostim™ System | Device: Barostim™ System<br>* Implantation of the Barostim™ System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Six Minute Hall Walk | Changes in Six Minute Hall Walk distance through 36 months post-implant | 36 months post-implant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Minnesota Living with Heart Failure Quality of Life | Changes in Minnesota Living with Heart Failure Quality of Life through 6 months post-implant | 6 months post-implant | 
| Change NYHA Class | Changes in NYHA Classification through 6 months post-implant | 6 months post-implant |
Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences

Study Overview
=================
Brief Summary
-----------------
Medical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. Participating in an observational clinical trial may help patients with non-small cell lung cancer since it advances medical knowledge and may improve treatment choices in the future.

Official Title
-----------------
Investigating Patients' Medical Study Experiences in Non-Small Cell Lung Cancer Clinical Trials to Identify Influencing Trends

Conditions
-----------------
Non-Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant has a diagnosis of non-small cell lung cancer Patient has self-identified as planning to enroll in a clinical trial for non-small cell lung cancer Patient is at least 18 years of age Exclusion Criteria: Inability to perform regular electronic reporting Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial Pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a non-small cell lung cancer clinical study. |  | 3 months | 
| Number of non-small cell lung cancer patients who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-small cell lung cancer
Accuracy Evaluation of Different All on Four Impression Techniques Using Plaster Jig

Study Overview
=================
Brief Summary
-----------------
This study will be conducted to evaluate the accuracy of different implant impression techniques using plaster jig Participants will have three types of impression techniques

Official Title
-----------------
Accuracy Evaluation of Different All on Four Impression Techniques Using Plaster Jig

Conditions
-----------------
Implant Prosthodontics

Intervention / Treatment
-----------------
* Procedure: Impression techniques


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non smokers Good oral hygiene Free from any signs of implant failure and requesting a fixed prosthesis Exclusion Criteria: patients that have severe bone resorption or excessive interarch space

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Digital impression<br>Digital impression using intraoral scanner | Procedure: Impression techniques<br>* 3 types of impression techniques for all on four<br>|
| Experimental: One stage open impression technique<br>Splinting impression long transfer and open tray impression technique | Procedure: Impression techniques<br>* 3 types of impression techniques for all on four<br>|
| Experimental: Two stage closed tray and open tray<br>Primary impression with closed tray impression techniques then secondary impression by open tray technique | Procedure: Impression techniques<br>* 3 types of impression techniques for all on four<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of impression technique | By using plaster jig | 3 months |